Every 8-K that INTEGRATED BIOPHARMA INC (INBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBP filings page.
Integrated BioPharma, Inc. (INBP) reported results for the quarter and fiscal year ended June 30, 2026. Quarterly revenue was $9.796 million, down 31.0% from $14.175 million a year earlier; the company recorded a $0.869 million operating loss and a $1.366 million net loss, versus operating income of $0.589 million and a net loss of $0.178 million.
Fiscal-year revenue differs between the results narrative and the statements of operations: the narrative reports $43.9 million, down 19.3% from $54.4 million, while the statements list $48.872 million for 2026 and $54.353 million for 2025. The statements also show a $2.705 million operating loss and $2.842 million net loss for 2026, versus $2.020 million operating income and $0.808 million net income in 2025. The two largest customers in the Contract Manufacturing Segment represented approximately 90% of total revenue in 2026, compared with 84% in 2025.
INTEGRATED BIOPHARMA, INC. (INBP) reported that its wholly owned subsidiary, Manhattan Drug Company, Inc. (MDC), has appointed Michael G. Richtmyer as Head of Operations. He joined MDC on August 3, 2026 and brings more than 35 years of senior operations and general management experience across pharmaceutical, nutraceutical, supplement, personal care, and contract manufacturing sectors.
Richtmyer will oversee operational strategy and execution at MDC, focusing on manufacturing performance, supply chain reliability, quality systems, productivity, and scalable growth. He previously served as President of Tishcon Corp., where he managed two vitamin, mineral, and supplement contract manufacturing sites and operations for more than 650 active products, and earlier worked with Integrated BioPharma from 1991 to 1999.
Integrated BioPharma, Inc. amended its loan agreement with PNC Bank, extending its existing committed revolving line of credit, which allows borrowings up to $4,000,000, to April 14, 2027. The company and its subsidiary also entered into a new $250,000 Convertible Line of Credit Note for equipment and vehicle purchases.
Before conversion, the new equipment line bears interest at a Daily Rate equal to one-month SOFR plus 250 basis points. The amendment also terminates a prior Convertible Equipment Line of Credit Note with a maximum amount of $500,000 that had matured and is no longer in effect.
Integrated BioPharma, Inc. reported weaker results for the quarter ended March 31, 2026, with revenue of $10.1 million versus $13.9 million a year earlier, a 27.3% decline. The company swung from operating income of about $0.7 million to an operating loss of about $1.1 million, and from net income of about $0.6 million to a net loss of about $0.8 million, or $(0.03) per diluted share.
For the nine months ended March 31, 2026, revenue was $34.1 million compared to $40.2 million, down 15.2%, with a net loss of about $1.5 million versus net income of about $1.0 million a year earlier. Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented about 90% of total revenue in the 2026 period, up from 83% in 2025, underscoring significant customer concentration.
Integrated BioPharma, Inc. reported that PNC Bank extended the expiration date of its line of credit, documented in an April 15, 2025 promissory note, from April 15, 2026 to July 14, 2026. The extension, which also covers subsidiary Manhattan Drug Company, Inc., becomes effective on April 16, 2026.
Integrated BioPharma Inc., through its wholly owned subsidiary Manhattan Drug Company, amended a long-term related-party lease for its office and warehouse space. The amendment reduces leased space from 116,175 to 110,095 square feet but raises annual basic rent from $845,966 to $1,100,950, with rent increasing three percent per year. The lease term is extended to a new termination date of January 31, 2029. Manhattan Drug Company will also continue to pay its proportionate share of the landlord’s operating expenses as additional rent. The landlord, Vitamin Realty Associates, is 100% owned by the estate of the company’s former chairman, a major stockholder, and the Co-Chief Executive Officers, who are also directors, making this a related-party arrangement.
Integrated BioPharma, Inc. reported weaker results for the quarter ended December 31, 2025, moving from profit to loss. Quarterly revenue fell to about $11.3 million from $12.6 million a year earlier, a 10.3% decline, and operating results shifted from roughly $0.2 million of income to a $0.9 million loss.
For the six-month period, revenue decreased to about $24.0 million from $26.2 million, and operating performance moved from approximately $0.7 million of income to a $0.7 million loss. The company recorded a net loss of $0.8 million for the quarter and $0.6 million for six months, versus net income of about $0.1 million and $0.4 million in the prior-year periods, with diluted earnings per share declining from $0.00 to $(0.03) for the quarter and from $0.01 to $(0.02) for six months.
Management noted that revenue from the two largest customers in the Contract Manufacturing Segment represented approximately 89% of total revenue for the six months ended December 31, 2025, up from 82% a year earlier, underscoring significant customer concentration.
Integrated BioPharma, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 1, 2025. Of 31,059,610 common shares entitled to vote as of October 17, 2025, holders of 22,651,488 shares were present in person or by proxy, establishing a quorum.
Stockholders elected Class III director Eric Friedman to serve until the 2028 Annual Meeting, with 20,662,516 votes for, 183,398 withheld and 1,805,574 broker non-votes. They approved, on a non-binding basis, holding the advisory vote on executive compensation every three years, with 20,395,034 votes supporting a three-year frequency.
Stockholders also gave non-binding approval to the executive compensation for the named executive officers, with 20,788,236 votes for, 56,978 against and 700 abstentions, plus 1,805,574 broker non-votes. In addition, they ratified the appointment of CBIZ CPAs P.C. as independent auditors for the fiscal year ending June 30, 2026, with 22,536,930 votes for, 113,420 against and 1,138 abstentions.
Integrated Biopharma, Inc. furnished an earnings press release for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and provides the company’s quarterly financial results.
The information was furnished under Item 2.02 and, along with Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists the exhibit index and confirms the materials are provided via Inline XBRL.
Integrated Biopharma, Inc. filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025. The filing states the press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The company clarifies the furnished information is not "filed" for Section 18 liability purposes and has attached the exhibit in Item 9.01.